Status:
TERMINATED
A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception
Lead Sponsor:
Medicines360
Conditions:
Contraception
Eligibility:
FEMALE
16-45 years
Phase:
PHASE3
Brief Summary
The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-te...
Detailed Description
This is a Phase 3, randomized, open-label, multicenter evaluation of the efficacy of a levonorgestrel-releasing intrauterine system (LNG20). The goals of the study include provision of information to ...
Eligibility Criteria
Inclusion
- Healthy women requesting contraception
- 16-35 years old
- Cohort 36-45 years old
- Sexually active
Exclusion
- Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy within 24 months of study entry
- Currently breastfeeding
- Current persistent, abnormal vaginal bleeding
Key Trial Info
Start Date :
November 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 12 2021
Estimated Enrollment :
1910 Patients enrolled
Trial Details
Trial ID
NCT00995150
Start Date
November 1 2009
End Date
October 12 2021
Last Update
August 14 2024
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States
2
Palo Alto, California, United States
3
San Francisco, California, United States
4
Vista, California, United States